KinasePro

Kinase Chemistry – Just a year and a half behind the times.

AACR NCI EORTC

Posted by kinasepro on October 22, 2007

Abstracts are up, and B is the one you’ll be looking for.

News of the day:

In pts [patients] with PRC, XL-880 demonstrated antitumor activity

Name Target Company Phase
AZD-2171 Vegf c-Kit Pdgfr-β AstraZeneca ph2
AZD-2171 Vegf c-Kit Pdgfr-β AstraZeneca ph2
PD-325901 Mek Pfizer ph2
XL-647 ErbB1,2 Vegfr-2 Exelixis ph2
XL-880 c-Met Vegf Exelixis ph2
ARQ-197 c-Met Arqule ph1
BAY-579352 Vegfr-2,3 c-Kit Pdgfr-β Bayer ph1
BAY-734506 c-Kit Ret Pdgfr Raf Bayer ph1
BIBW-2992 ErbB (irrev) BI ph1
PD-325901 Mek Pfizer ph1
PF-299804 ErbB (irrev) Pfizer ph1
Ticribine Akt VioQuest ph1
XL-647 ErbB 1,2 Vegfr-2 Exelixis ph1
XL-820 Vegfr c-Kit Pdgfr Exelixis ph1
XL-880 c-Met Vegf Exelixis ph1
ARRY-543 ErbB1, 2 Array ph1
AT-13148 Akt Rock PKA Astex  
AV-951 Vegf Aveo ph1
BAY-734506 c-Kit Ret Pdgfr Raf Bayer  
BMS-698769 c-Met BMS  
CEP-11981 Tie2 Vegfr Cephalon  
CUDC-101 HDAC / ErbB Curis  
NVP-BEZ235 Pi3k Novartis  
OSI-906 IGF-1R Osi  
RDEA-119 Mek Ardea  
SGX-523 c-Met SGX  
SR-13654 Src SRI  
XL-765 Pi3k, mTOR Exelixis  
XL-820 c-Kit Exelixis  
XL-844 Chk1, 2 Exelixis  
ZD-6474 Vegfr-2 EGFR    
ZM 447439 Aurora    
CRT-59359 PKD CRT  

Duplicates and phase field just reflect the subject of the poster / reported trial, click for more details.

Advertisements

One Response to “AACR NCI EORTC”

  1. Petros said

    For AV-412 structure see process patent WO-2007103233

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: